Jan 8, 2013 by Brenton FlynnIs This Vaccine a Diabetes Play?Could this hepatitis-B vaccine turn into a diabetes play?
Jan 8, 2013 by Brenton Flynn3 Bullish Signs From a Struggling BiotechA bull's view of Dendreon's conference presentation.
Jan 8, 2013 by Brenton FlynnShould You Buy the Regeneron Sell-Off?Is this an opportunity to invest in high-flying Regeneron?
Jan 8, 2013 by Brenton FlynnMAKO Provides a Sneak PeekWe get to see some key metrics from MAKO's Q4 before the company officially releases earnings.
Jan 7, 2013 by Brenton FlynnBig News for These 2 Diabetes HopefulsGreat news for investors in the enormous diabetes market.
Jan 7, 2013 by Brenton FlynnDendreon Offers a Sneak PeekDendreon releases preliminary quarterly results.
Jan 7, 2013 by Brenton FlynnThis Hepatitis-C Player Is Struggling TodayAnything less than perfection doesn't cut it
Jan 7, 2013 by Brenton FlynnUp 70%, Peregrine's Clinical Lemon Becomes LemonadeTurning clinical data lemons into lemonade.
Jan 4, 2013 by Brenton FlynnFriday's Best and Worst Health Care StocksOne big up and one big down in the biotech space today.
Jan 4, 2013 by Brenton FlynnIs This the Right Way to Play Biotech?This Biotech ETF isn't my best bet.
Jan 4, 2013 by Brenton FlynnThe Better Way to Play BiotechIf you're going the ETF route, this product appears to be the best option
Jan 3, 2013 by Brenton FlynnBig Pharma, Bigger OverhangsToo risk averse for biotech? These big pharmas could be your ticket.
Jan 3, 2013 by Brenton Flynn, Dave Williamson, and Max MacalusoWill These Risks Crush Questcor in 2013?What are the biggest overhangs facing this biotech company?
Jan 3, 2013 by Brenton Flynn, Dave Williamson, and Max Macaluso1 Big Long-Term Risk for Medical DevicesAs payer's increasingly scrutinize costs, will these companies lose out?
Jan 3, 2013 by Brenton Flynn and Max MacalusoWhat Should You Think of the New Abbott Labs?Now that Abbott Labs has slimmed down and lost its branded pharmaceuticals division by spinning off the new AbbVie, what should investors make of it?
Jan 2, 2013 by Brenton Flynn and Max MacalusoAbbVie: Pharma's New Kid on the BlockThe Abbott Labs spin-off AbbVie is officially on the market.
Dec 31, 2012 by Brenton Flynn and Dave WilliamsonShould You Spin AbbVie Out of Your Portfolio?Time to part ways?
Dec 22, 2012 by Brenton Flynn2 Winners From the Medical Robot ApocalypseWithout the Mayans, we need a new apocalypse to worry about. Why not robots? Medical robots, to be exact.
Dec 21, 2012 by Brenton FlynnWill the Robot Bear Raid Hurt MAKO?Will MAKO Surgical also suffer at the hands of this bear?
